Dendrite Announces Schering-Plough to Enhance Sales Force Effectiveness and Business Planning Solution With Dendrite's Proven .

Dendrite International, Inc. (NASDAQ:DRTE), a leading
provider of pharmaceutical industry solutions, today announced that
Schering Corporation, a subsidiary of Schering-Plough Corporation, has
signed a five-year agreement to enhance VISION, its proprietary sales
force effectiveness (SFE) and business planning solution, for its
U.S.-based pharmaceutical field sales organization. As a result,
Dendrite will seamlessly integrate components of its proven .NET
framework with Schering-Plough's VISION system to facilitate the sales
force in managing customer information and recording call activity.
   Dendrite's .NET framework provides compelling capability to make
sales representatives and managers more efficient and productive in
their selling activities. Field sales organizations can benefit from
Dendrite's revolutionary system navigation, built on human-centered
design principles that mirror the workflow of the representative. By
matching sales force tools to workflow, representatives can maximize
the number of prescriber visits and the quality of each prescriber
interaction.
   Augmenting the expanded capabilities of Schering-Plough's VISION
system will be Sample Guardian(TM), Dendrite's integrated home office
sample management and reconciliation solution. Pharmaceutical
companies benefit from having a flexible and cost effective
alternative for tracking, analyzing, reporting, and storing all drug
sample activity data. Sample Guardian, and associated custom reports
developed together with Dendrite, assists pharmaceutical companies
with ongoing efforts to comply with Food and Drug Administration (FDA)
and Prescription Drug Marketing Act (PDMA) regulations.
   "Leveraging Dendrite for pharma-specific business process
enhancements will give Schering-Plough access to the latest and most
effective technologies, proven methodologies and best practices, and
support through highly trained personnel with extensive pharmaceutical
experience, allowing for continued focus on their core business of
developing therapies and having a positive impact on patient lives,"
said Natasha Giordano, president of global accounts for Dendrite.

   About Dendrite

   Founded in 1986, Dendrite International (NASDAQ:DRTE) enables
sales, marketing, clinical and compliance solutions for the global
pharmaceutical industry. The Company's clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies. For more information, please visit www.dendrite.com.

   Note: Dendrite is a registered trademark of Dendrite
International, Inc.

   This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our solutions;
our fixed expenses in relation to fluctuating revenues and variations
in customers' budget cycles; dependence on certain major customers;
changes in demand for our products and services attributable to any
weakness experienced in the economy or mergers, acquisitions and
consolidations in the pharmaceutical industry; successful and timely
development and introduction of new products and versions; rapid
technological changes; increased competition; international
operations; integrating the entities we acquire; our ability to
effectively manage our growth; the protection of our proprietary
technology; our ability to compete in the Internet-related products
and services market; the continued demand for Internet-related
products and services; the ability of our third party vendors to
respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than
anticipated results from strategic relationships; dependence of data
solutions on strategic relationships; events which may affect the U.S.
and world economies; and catastrophic events which could negatively
affect our information technology infrastructure. Other important
factors that should be reviewed and carefully considered are included
in the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to reflect
actual results, changes in assumptions or other changes affecting such
forward-looking statements and the information provided in this press
release should not be construed as updating, modifying or confirming
the company's most recent financial outlook or guidance.